Savara Obtains Global Rights to Develop and Commercialize Apulmiq

Go back to Savara Obtains Global Rights to Develop and Commercialize Apulmiq
(NASDAQ: SVRA) Delayed: 6.03 -0.26 (4.13%)
Previous Close $6.29    52 Week High
Open $6.29    52 Week Low
Day High $6.29    P/E N/A 
Day Low $5.93    EPS
Volume 1,720,421